A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The global prevalence of MASLD is substantial, with estimates ranging from 30% to 32%, and the incidence of associated conditions like liver ... of fat storage. GLP-1 receptor agonists (GLP ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Structure Therapeutics Inc. has selected a lead oral small-molecule amylin receptor agonist, ACCG-2671, for the treatment of obesity. ACCG-2671 is a dual amylin and calcitonin receptor agonist (DACRA) ...

Study: Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective. Image Credit: crystal light / Shutterstock ...

Polyphenols are a diverse group of compounds that contribute to the flavor and health benefits of foods like green tea, berries, and dark chocolate. Among these compounds, flavonoids—responsible for ...

GLP-1 receptor agonists emerge as promising therapies for MASLD, addressing metabolic dysfunction and offering potential improvements in liver health and fibrosis management. Study: Current Status of ...